Skip to content

Study · Non-randomized trial · 1998

8 results

Cutaneous reactions and sensations after intracutaneous injection of vasoactive intestinal polypeptide and acetylcholine in atopic eczema patients and healthy controls.

Rukwied R, Heyer G

Archives of dermatological research1 Apr 1998Cited by 16 (Europe PMC)

PMID9617439 (opens in a new tab)DOI10.1007/s004030050290 (opens in a new tab)PepBankPUB-09617439
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    Intracutaneous VIP increased laser Doppler blood flow in the forearm skin of atopic eczema patients and healthy controls.

    In plain wordsIn people with atopic eczema and healthy people, VIP injected into the skin increased blood flow in the skin.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseBlood flow (laser Doppler) after VIP injection
    Study

    n: not reported in source

    Outcome group
    Skin reactions · Skin and wound
    Studied dose
    1.5 x 10(-7) to 1.5 x 10(-5) M · intracutaneousAs given in this study (human).

    Source sentences

    Summary
    Both substances led to an increase in LDF measurements and induced a wheal and flare reaction.
    1 context sentence
    Summary · context
    Three groups of subjects (controls, AE patients suffering from acute eczema and AE patients during a symptom-free period) were investigated.
  2. 02HumanNon-randomized trialEfficacy outcome

    Intracutaneous VIP induced a wheal and flare reaction in the forearm skin of atopic eczema patients and healthy controls.

    In plain wordsIn people with atopic eczema and healthy people, VIP injected into the skin caused a wheal and flare skin reaction.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseWheal and flare reaction after VIP injection
    Study

    n: not reported in source

    Outcome group
    Skin reactions · Skin and wound
    Studied dose
    1.5 x 10(-7) to 1.5 x 10(-5) M · intracutaneousAs given in this study (human).

    Source sentences

    Summary
    Both substances led to an increase in LDF measurements and induced a wheal and flare reaction.
    1 context sentence
    Summary · context
    Three groups of subjects (controls, AE patients suffering from acute eczema and AE patients during a symptom-free period) were investigated.
  3. 03HumanNon-randomized trialEfficacy outcome

    Blood flow rose with the dose of a single VIP injection in controls and in both groups of atopic eczema patients.

    In plain wordsIn all groups, higher VIP doses injected into the skin raised blood flow more.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseDose-dependent blood flow after single VIP injection
    Study

    n: not reported in source

    Outcome group
    Skin reactions · Skin and wound
    Studied dose
    1.5 x 10(-7) to 1.5 x 10(-5) M · intracutaneousAs given in this study (human).

    Source sentences

    Summary
    Blood flow was elevated as a function of dose after a single VIP application in all groups.
    1 context sentence
    Summary · context
    Three groups of subjects (controls, AE patients suffering from acute eczema and AE patients during a symptom-free period) were investigated.
  4. 04HumanNon-randomized trialEfficacy outcome

    After single VIP injection, flare area was significantly reduced in atopic eczema patients compared with healthy controls.

    In plain wordsAfter VIP injected into the skin, people with atopic eczema had a smaller flare area than healthy controls.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseFlare area after single VIP injection versus healthy controls
    Study

    n: not reported in source

    Comparator
    Healthy controls
    Outcome group
    Skin reactions · Skin and wound
    Studied dose
    1.5 x 10(-7) to 1.5 x 10(-5) M · intracutaneousAs given in this study (human).

    Source sentences

    Summary
    Compared with healthy controls, a significant increase in blood flow was measured after combined VIP and ACh administration in AE patients suffering from acute AE, whereas flare area and plasma extravasation were significantly reduced after single VIP and combined VIP and ACh injections, respectively.
    1 context sentence
    Summary · context
    Three groups of subjects (controls, AE patients suffering from acute eczema and AE patients during a symptom-free period) were investigated.
  5. 05HumanNon-randomized trialEfficacy outcome

    VIP induced dose-dependent pruritus in all groups.

    In plain wordsIn controls and in people with atopic eczema, higher VIP doses injected into the skin caused more itching.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseDose-dependent pruritus after VIP injection
    Study

    n: not reported in source

    Outcome group
    Skin reactions · Skin and wound
    Studied dose
    1.5 x 10(-7) to 1.5 x 10(-5) M · intracutaneousAs given in this study (human).

    Source sentences

    Summary
    In all groups, VIP induced dose-dependent pruritus.
    1 context sentence
    Summary · context
    Three groups of subjects (controls, AE patients suffering from acute eczema and AE patients during a symptom-free period) were investigated.
  6. 06HumanNon-randomized trialEfficacy outcome

    Combined injections of VIP and acetylcholine had no additional effect on the magnitude of the sensation compared with a control stimulus.

    In plain wordsInjecting VIP and acetylcholine together did not change how strong the sensation felt compared with the control injection.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeSensation magnitude after combined VIP and ACh versus control stimulus
    Study

    n: not reported in source

    Comparator
    Control stimulus (0.9% sodium chloride and ACh)
    Outcome group
    Skin reactions · Skin and wound
    Studied dose
    1.5 x 10(-7) to 1.5 x 10(-5) M · intracutaneousAs given in this study (human).

    Source sentences

    Summary
    Compared with a control stimulus (0.9% sodium chloride and ACh), combined injections of VIP and ACh had no additional effect on the magnitude of the sensation.
    1 context sentence
    Summary · context
    Three groups of subjects (controls, AE patients suffering from acute eczema and AE patients during a symptom-free period) were investigated.

Studies that did not test the peptide alone2

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 07HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneNon-randomized trialEfficacy outcome

    After combined VIP and acetylcholine injection, blood flow was significantly higher in patients with acute atopic eczema than in healthy controls.

    In plain wordsAfter VIP and acetylcholine were injected together, patients with acute atopic eczema had more skin blood flow than healthy controls.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseBlood flow after combined VIP and ACh, acute atopic eczema versus healthy controls
    Study

    n: not reported in source

    Comparator
    Healthy controls
    Outcome group
    Skin reactions · Skin and wound

    Source sentences

    Summary
    Compared with healthy controls, a significant increase in blood flow was measured after combined VIP and ACh administration in AE patients suffering from acute AE, whereas flare area and plasma extravasation were significantly reduced after single VIP and combined VIP and ACh injections, respectively.
    1 context sentence
    Summary · context
    Three groups of subjects (controls, AE patients suffering from acute eczema and AE patients during a symptom-free period) were investigated.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  2. 08HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneNon-randomized trialEfficacy outcome

    After combined VIP and acetylcholine injection, plasma extravasation was significantly reduced in atopic eczema patients compared with healthy controls.

    In plain wordsAfter VIP and acetylcholine were injected together, people with atopic eczema had less fluid leaking from skin vessels than healthy controls.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreasePlasma extravasation after combined VIP and ACh versus healthy controls
    Study

    n: not reported in source

    Comparator
    Healthy controls
    Outcome group
    Skin reactions · Skin and wound

    Source sentences

    Summary
    Compared with healthy controls, a significant increase in blood flow was measured after combined VIP and ACh administration in AE patients suffering from acute AE, whereas flare area and plasma extravasation were significantly reduced after single VIP and combined VIP and ACh injections, respectively.
    1 context sentence
    Summary · context
    Three groups of subjects (controls, AE patients suffering from acute eczema and AE patients during a symptom-free period) were investigated.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.